Predictive Oncology

At Predictive Oncology, we know there is a cancer patient waiting for therapies to be developed, hoping for a new and effective treatment to get into the hands of the clinician that can help improve their quality of life, extend their life or even cure their cancer. In honor of International Women’s Day, we would like to thank the women at Predictive Oncology who work tirelessly to bring that hope to cancer patients.

Proactive Investor’s Natalie Stoberman met with Raymond F. Vennare, CEO of Predictive Oncology, and Javier Torres-Roca, MD, Co-Founder and CEO of Cvergenx, Inc., to discuss their strategic partnership to create the first-ever genomics-based approach to precision radiation therapy and drug discovery using artificial intelligence.

You can view the interview here and learn more about how this powerful collaboration will leverage Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities with the Cvergenx precision genomics radiation therapy platform.

Predictive Oncology partners with Cvergenx to create new genomics-based A.I. radiation therapy Predictive Oncology CEO Raymond Vennare and Cvergenx CEO Javier Torres-Roca join Natalie Stoberman to share their new partnership to develop the first-ever...

Predictive Oncology is pleased to announce that we have signed an agreement to form a strategic partnership that has the potential to revolutionize the field of radiation oncology with the first-ever genomics-based artificial intelligence approach to personalized radiotherapy and drug discovery.

By applying Predictive Oncology’s drug discovery, artificial intelligence and machine learning capabilities (PEDAL), and the Cvergenx precision genomics radiation therapy platform (pGRTTM), the two companies will pursue ways in which to optimize radiotherapy (RT) to improve patient outcomes in a way that has never been done before.

More than one million patients are treated with radiotherapy every year in the US. If the overall survival of RT-treated patients is improved by 4%, that would translate into 40,000 lives, almost equivalent to eradicating breast cancer. We believe this knowledge can improve the clinical outcome of patients treated with radiotherapy.

The pGRT platform is currently being evaluated in a Phase 2 prospective clinical trial for triple negative breast cancer (NCT05528133) at the Moffitt Cancer Center. Cvergenx is a spin-out of the Moffitt Cancer Center.

Learn more about the news here:
https://investors.predictive-oncology.com/news-releases/news-release-details/predictive-oncology-and-cvergenx-announce-partnership-develop-0

Moffitt Cancer Center

If you work for an academic or research institution and are involved in oncology drug discovery, we invite you to apply to the Predictive Oncology ACE program that we launched today.

Our company created ACE (Accelerating Compound Exploration) to grant early-stage academic drug development groups and technology transfer offices access to our PEDAL platform. PEDAL pairs active machine learning with an extensive biobank of 150K privately held tumor samples and in vitro assay results to help evaluate drug compounds and enable more informed selection of drug-tumor type combinations.

The deadline for the first round of applications is March 31.

ACE intake - Predictive Oncology ACE program Introducing the Predictive Oncology ACE program Welcome to the ACE (Accelerating Compound Exploration) program, an initiative we are launching at Predictive Oncology to help academic and research institutions to advance their drug discovery. Our company created ACE to grant early-stage a...

“The ability to use the PEDAL platform and testing in actual tumor samples to determine the drug response of these tumors is going to be…invaluable to drug discovery teams,” Pamela Bush, Ph.D., MBA, Chief Business Officer, Predictive Oncology.
https://hubs.la/Q01CCXZW0

Determining drug response The ability to use the PEDAL platform and testing in actual tumor samples to determine the drug response of these tumors is going to be invaluable to drug di...